Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Madras High Court...

    Madras High Court steps in to cut dependency on Chinese drugs for cancer

    Written by Ruby Khatun Khatun Published On 2018-05-31T16:36:07+05:30  |  Updated On 31 May 2018 4:36 PM IST
    Madras High Court steps in to cut dependency on Chinese drugs for cancer

    Chennai: The Madras High Court appointed advocate N L Rajah as amicus curiae to look into the possibilities of encouraging domestic manufacturers of cancer drugs to avoid dependency on Chinese-made ones.


    Justice N Kirubakaran, who passed an interim order, directed Rajah to report on the rising incidents and spread of cancer and medicines for the treatment of the deadly disease.


    The issue pertains to a plea moved by Vinkem Labs Limited, a domestic manufacturer, claiming that overwhelming dependence on drugs and raw material from China, particularly those for cancer treatment, could prove harmful to those in the Indian health sector.


    The company wanted the court to direct the central government to provide more preference to the indigenous manufacturers than Chinese ones.


    It sought to achieve self-reliance for seven critical active pharmaceutical ingredient molecules in cancer treatment.


    The petitioner claimed every 13th cancer patient in the world is an Indian. Two women succumb to the disease every 10 minutes, while 50 children die every day, the company submitted.


    According to the petitioner, over 90 percent of raw material for the manufacture of cancer drugs are imported from China.


    When the plea came up today, the judge said, "If the petitioner is given the required assistance, the petitioner is sure that he could manufacture cancer drugs at a lower rate, as he developed extensive know-how in generic cancer drugs and ultimately the dependence on China would be reduced considerably."


    In its response, the government submitted that its intent is to implement the recommendations of the Katoch committee to bring down the dependence on foreign drug-makers, but in the meantime, the petitioner cannot seek a general direction for preferential allotment/quota.


    The court then said that the amicus curiae would report the progress of the evaluation to the court on June 11 and submit a report on June 27.

    Active Pharmaceutical Ingredientadvocate N L Rajahamicus curiaecancerchinaChinese drugsCourtcutdependencydomestic manufacturersJustice N KirubakaranMadras High Courtpreferential allotmentVinkem Labs Limited
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok